Do We Still Need 5α-Reductase Inhibitors for Patients with Benign Prostatic Hyperplasia After the PARTEM Study?
Cardiovasc Intervent Radiol
.
2023 Oct;46(10):1428-1429.
doi: 10.1007/s00270-023-03526-7.
Epub 2023 Aug 8.
Author
Tiago Bilhim
1
Affiliation
1
Consultant Interventional Radiologist, Interventional Radiology Unit, Centro Hospitalar Universitário de Lisboa Central (CHULC), Lisbon, Portugal. tiagobilhim@hotmail.com.
PMID:
37553447
DOI:
10.1007/s00270-023-03526-7
No abstract available
Publication types
Editorial
MeSH terms
5-alpha Reductase Inhibitors* / therapeutic use
Humans
Male
Oxidoreductases
Prostatic Hyperplasia* / drug therapy
Substances
5-alpha Reductase Inhibitors
Oxidoreductases